minocycline and Head-and-Neck-Neoplasms

Local/systemic symptoms during cancer therapy may be exacerbated by dysregulated inflammation and its downstream toxic effects. Minocycline can suppress proinflammatory cytokine release; therefore, we investigated its potential to reduce patient-reported symptom severity during radiotherapy (RT) for head and neck cancer (HNC).. Eligible patients for this blinded, placebo-controlled trial were adults with T0-3, N-any, and M0 HNC receiving single-modality RT. Participants were randomized 1:1 to either minocycline (200 mg/day) or placebo during RT. The primary endpoint was the area under the curve (AUC) of 5 prespecified symptoms (pain, fatigue, disturbed sleep, poor appetite, difficulty swallowing/chewing) during RT, assessed with the MD Anderson Symptom Inventory for HNC (MDASI-HN).. We analyzed data from 20 evaluable patients per arm. Overall, 75% had oropharyngeal cancer and 78% were male. No grade 3+ adverse events potentially related to study medication were observed. Two minocycline patients required a feeding tube during RT vs 5 placebo patients (P = 0.21). The average daily AUC during RT for the 5 MDASI-HN symptoms was 3.1 (SD = 1.0) for minocycline and 3.7 (SD = 1.7) for placebo (P = 0.16); the 0.37 effect size was less than our 0.70 target. AUC comparisons for several individual symptoms and symptom interference favored minocycline but were not statistically significant. The greatest numerical differences occurred for systemic symptoms, larger toward treatment end, and in early post-RT recovery.. Minocycline was feasible, well tolerated, and achieved a positive signal toward reducing patient-reported symptom severity during RT for HNC, particularly for systemic symptoms. This justifies additional study and informs future trial design.

Topics: Aged; Combined Modality Therapy; Deglutition Disorders; Fatigue; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Minocycline; Pain; Radiodermatitis; Sleep Wake Disorders; Treatment Outcome

To explore whether antibacterial drug tigecycline could exert an antitumoral effect in oral squamous cell carcinoma (OSCC).. Two OSCC cell lines Tca8113 and KB were used in this study. To investigate the cytostatic effects of tigecycline in OSCC, cell growth was tested by trypan blue staining, MTT assay, and Brdu immunofluorescence staining. Then, the apoptosis proportion was measured by FITC Annexin-V and PI labeling, and cell cycle was determined by PI staining. The expression of caspase 3 (CASP3) and cell cycle regulatory protein was detected by Western blot assay. Finally, the clonogenesis and tumorigenesis capacity were analyzed by soft agar growth and xenograft model.. Here, we showed that tigecycline significantly inhibited cell growth and proliferation in OSCC cell lines Tca8113 and KB. It did not induce cell apoptosis but led to an increase of cells in G0/G1 phase with down-regulation of cyclin E2 (CCNE2) and cyclin-dependent kinase4 (CDK4) protein expression. We also showed that tigecycline inhibited colony formation in soft agar and reduced tumor growth in a xenograft model.. Our results suggested that tigecycline might be used as a novel candidate agent for the treatment of OSCC.

Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Cyclins; Down-Regulation; Head and Neck Neoplasms; Heterografts; Humans; Mice; Mice, SCID; Minocycline; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Tigecycline; Tumor Stem Cell Assay

Necrotizing fasciitis is a severe polybacterial infection characterized by necrosis of the fascia and adjacent soft tissues with rapid expansion of the infection along the fascial planes. It is a rare and potentially fatal entity in the head and neck region. We present 2 patients with head and neck cancers who developed necrotizing fasciitis during the postoperative period.

Topics: Acinetobacter baumannii; Adult; Colistin; Fasciitis, Necrotizing; Head and Neck Neoplasms; Humans; Imipenem; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Minocycline; Postoperative Period; Pseudomonas aeruginosa; Thienamycins; Tigecycline

Topics: Adult; Carcinoma, Papillary; Female; Head and Neck Neoplasms; Humans; Minocycline; Thyroid Gland; Thyroid Neoplasms

Topics: Adult; Aged; Carcinoma; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymph Node Excision; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Surgical Wound Infection; Tetracyclines